B1 Proteins & Enzymes · Protein engineering · Fibrinolytic variants

Staphylokinase Variant Screening Platform

Rank hundreds of variants without purifying each one. A cell-free expression platform scores staphylokinase variants by activity directly from unpurified reactions — built for engineering campaigns where variant numbers make conventional screening impractical.

Book a 30-minute discovery call Request the data package

Evidence: Publication reported 2026 · data package under NDA
Stage: Pilot-ready · co-development open
Indicative: € 12 000 – 60 000co-development quoted individually

What the platform does

Conventional variant screening forces you to purify every candidate before you can measure it, which caps how many variants a campaign can realistically test. This platform expresses variants cell-free and ranks them by activity directly from unpurified reactions, so the purification step moves to the end of the funnel instead of the beginning.

Where it changes the economics

The saving is proportional to library size. For a campaign of a few variants it is not worth it; for hundreds, the difference between purifying everything and purifying the top ranks is the difference between a feasible project and an abandoned one.

Applications

Fibrinolytic protein engineering
Activity ranking of large variant sets
Hit triage before purification
Co-development on partner targets

Assays & readouts available

Cell-free expression of variant panels
Activity-based ranking from unpurified material
Confirmation on purified top candidates
Protocol transfer to the partner

Specification

Technology type	Cell-free expression + activity-based variant ranking
Research group	CIB — Centre for Interdisciplinary Biosciences (prof. Sedlák)
Evidence status	Publication reported for 2026; full citation and method data supplied under NDA
Typical pilot	Custom research pilot, 8–12 weeks
Deliverables	Ranked variant list, activity data, method report
Engagement	Feasibility scan · pilot · co-development
Indicative price	€ 12 000 – 60 000 · co-development quoted individually

Fibrinolytic activity measured in vitro is not a statement about therapeutic efficacy, safety or regulatory status. Any clinical route is the partner's own programme.

What happens next

Book a call or send an inquiry. Tell us the target, the application and the timeline.
We answer within three working days — including when the answer is that we cannot help.
NDA before disclosure, if you need one. Tick the box on the form.
Feasibility scan or pilot proposal with a defined scope, deliverable and price.

Book a 30-minute discovery call Send an inquiry

Common questions

How does an engagement start?

With a free 30-minute discovery call. We establish whether there is a fit and what the right next step is. Nothing is committed at that point.

Can we sign an NDA before we describe our project?

Yes. Tick the NDA box on the inquiry form and we arrange it before any disclosure.

Are the prices on this site binding?

No. They are indicative ranges so that you can size a project before contacting us. Final terms are negotiated per scope.

How quickly do you reply?

Every inquiry is acknowledged within one working day and answered by the responsible group leader within three.

What happens if you cannot help?

We say so, early, and where we can we point you to someone who can. A negative feasibility answer delivered quickly is a useful result.

Related in Proteins & Enzymes

Enzyme engineering · Directed evolution

Haloalkane Dehalogenase Engineering Platform

Carbon–halogen bond cleavage for remediation and industrial process chemistry. Directed evolution, ribosome display and catalytic optimisation applied to your substrate — relevant wherever a process generates or handles halogenated streams.

Evidence: Capability & method data under NDA
Stage: Pilot-ready · licensing open
Indicative: € 15 000 – 120 000negotiable by scope and application

View details Discuss this

Protein biophysics · Formulation support

Protein Stability & Formulation Platform

Know before you formulate. DSC, fluorescence probes and dynamic light scattering map thermodynamic and kinetic stability; buffer, salt and pH screening and aggregation risk profiling are run on your protein rather than on a generic prediction.

Evidence: Method portfolio · report under NDA
Stage: Pilot-ready
Indicative: € 8 000 – 50 000negotiable by scope and application

View details Discuss this

Protease activity · Condition optimisation

HRV 3C Protease Optimisation Platform

Kosmotropic anions increase HRV 3C protease rigidity, stability and catalytic efficiency — a published finding with direct workflow consequences. If your production depends on a cleavage step, this tells you which conditions maximise yield and enzyme lifetime.

Evidence: Peer-reviewed 2022 (Biophys. Chem.)
Stage: Pilot-ready
Indicative: € 6 000 – 35 000negotiable by scope and application

View details Discuss this

Tell us what you are trying to achieve.

A free 30-minute call establishes whether there is a fit and what the right next step is. Every inquiry is acknowledged within one working day and answered by the responsible group leader within three.

Book a 30-minute discovery call Send an inquiry instead